EGFR and non-small cell lung carcinoma: Together, the above findings demonstrate that MPEG-PLA nanoparticles co-encapsulating EGFR inhibitors and integrin αvβ3 inhibitor Cilen could reverse the EGFR resistance along with reduced organ damages, which provides potential strategy for clinical NSCLC treatment.